Shortly after the start of the pandemic in spring 2020, MultiplexDX completed the development of the first of a total of nine PCR tests, of which more than 250,000 were donated to combat the pandemic in the Slovak Republic, Vatican, Ukraine, Slovenia, Serbia, Montenegro, and Moldova. "The main task of science is to help. At a time when the whole world was facing a big unknown, the decision for us to go into the development of tests, as well as donate them, was the only right thing to do," explains P. Čekan.
He adds that he very much appreciates that the efforts not only of the team in MultiplexDX, but also of all scientists involved in the fight against the pandemic, were noticed both by important public institutions, as well as the public. "We hope that the contribution of science will not be forgotten even after the pandemic. The globalized world brings challenges that we cannot meet without science, whether it is in the field of health, but also in the field of sustainability, and many others," adds P. Čekan.
In addition to the second-highest civilian award from the President of the Slovak Republic, Pavol Čekan together with Boris Klempa from the Biomedical Center of the Slovak Academy of Sciences received an award for assistance in setting up pandemic measures for schools in Bratislava - Old Town. Last but not least, the Slovak Chemical Society also awarded Pavel Čekan the Gold Medal for his contribution to chemical research and its application for the benefit of society as a whole.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.